Entero Healthcare Solutions Limited has informed the Exchange regarding Grant of 7300 Options.

Entero Healthcare reported standalone profit after tax of Rs. 268.75 million for FY26, up 40% from Rs. 191.81 million in FY25, despite a 15% decline in standalone revenue to Rs. 3,482.41 million. On a consolidated basis, the company showed stronger performance with revenue growing 29% to Rs. 65,912.12 million and PAT rising 36% to Rs. 1,458.40 million. The board approved allotment of 7,240 equity shares upon exercise of vested ESOPs and granted 7,300 fresh employee stock options under the Entero ESOP Plan 2023. Three independent directors were reappointed for a second term. The company also announced acquisition of Vishal Surgicals and Vishal Surgicals & Medicals through its subsidiary Sai Pharma Distributors. During FY26, Entero completed 7 new subsidiary acquisitions and divested Suprabhat Pharmaceutical, while its internal restructuring via amalgamation of subsidiaries into Rada Medisolutions was approved by MCA.